Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
Regeneron(REGN) stock is priced at $693.20, giving the company a market capitalization of 72.89B. It carries a P/E multiple of 16.64 and pays a dividend yield of 38.0%.
On 2025-11-14, Regeneron(REGN) stock moved within a range of $686.00 to $699.27. With shares now at $693.20, the stock is trading +1.0% above its intraday low and -0.9% below the session's peak.
Trading activity shows a volume of 898.42K, compared to an average daily volume of 957.99K.
The stock's 52-week range extends from a low of $476.49 to a high of $803.42.
The stock's 52-week range extends from a low of $476.49 to a high of $803.42.
REGN News
Regeneron (REGN) Pharmaceuticals announced new and updated data from its hematology portfolio and pipeline will be shared across 14 abstracts at the American So...
Key Points These two healthcare giants have impressive growth potential for different reasons. Eli Lilly is getting a lot of attention for its GLP-1 successes...
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron and keeping the price target at $725.00. Meet Your ETF AI Analyst Discover how TipR...
Analyst ratings
70%
of 30 ratingsMore REGN News
Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Regeneron and keeping the price target at $767.00. Meet Your ETF AI Analyst Discover how Ti...
Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Inv...
Regeneron Pharmaceuticals, Inc.'s ( ) stock showed strength, with investors undeterred by its weak earnings report. We think that shareholders might be missing...
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging results from two Phase 2 clinical trials evaluating its investigational factor XI antibo...